PT1268480E - Derivados de 8-quinolinil-xantina e 8-isoquinolinil-xantina como inibidores da pde 5 - Google Patents

Derivados de 8-quinolinil-xantina e 8-isoquinolinil-xantina como inibidores da pde 5

Info

Publication number: PT1268480E
Authority: PT; Portugal
Prior art keywords: xantin; isokinolinyl; pde; quinolinyl; inhibitors
Prior art date: 2000-04-07

Application number

PT01940294T

Other languages

English (en)

Inventor

Stephen Paul Collingwood

Gurdip Bhalay

Robin Alec Fairhurst

Sylvie Felicite Gomez

Reto Naef

David Andrew Sandham

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-07

Filing date

2001-04-05

Publication date

2004-03-31

2001-04-05 Application filed by Novartis Ag filed Critical Novartis Ag

2004-03-31 Publication of PT1268480E publication Critical patent/PT1268480E/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Nutrition Science (AREA)
Pregnancy & Childbirth (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)

PT01940294T 2000-04-07 2001-04-05 Derivados de 8-quinolinil-xantina e 8-isoquinolinil-xantina como inibidores da pde 5 PT1268480E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0008694.2A GB0008694D0 (en)	2000-04-07	2000-04-07	Organic compounds

Publications (1)

Publication Number	Publication Date
PT1268480E true PT1268480E (pt)	2004-03-31

Family

ID=9889516

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT01940294T PT1268480E (pt)	2000-04-07	2001-04-05	Derivados de 8-quinolinil-xantina e 8-isoquinolinil-xantina como inibidores da pde 5

Country Status (29)

Country	Link
US (1)	US20030171384A1 (pt)
EP (1)	EP1268480B1 (pt)
JP (1)	JP3869725B2 (pt)
KR (1)	KR100526094B1 (pt)
CN (1)	CN1176922C (pt)
AR (1)	AR028531A1 (pt)
AT (1)	ATE253576T1 (pt)
AU (2)	AU7392101A (pt)
BR (1)	BR0109855A (pt)
CA (1)	CA2403514C (pt)
CZ (1)	CZ20023305A3 (pt)
DE (1)	DE60101158T2 (pt)
DK (1)	DK1268480T3 (pt)
ES (1)	ES2210169T3 (pt)
GB (1)	GB0008694D0 (pt)
HU (1)	HUP0300565A3 (pt)
IL (1)	IL152078A0 (pt)
MX (1)	MXPA02009903A (pt)
MY (1)	MY119238A (pt)
NO (1)	NO20024741L (pt)
NZ (1)	NZ521361A (pt)
PE (1)	PE20020228A1 (pt)
PL (1)	PL212407B1 (pt)
PT (1)	PT1268480E (pt)
RU (1)	RU2269529C2 (pt)
SK (1)	SK14282002A3 (pt)
TR (1)	TR200400185T4 (pt)
WO (1)	WO2001077110A1 (pt)
ZA (1)	ZA200207956B (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10135815A1 (de) *	2001-07-23	2003-02-06	Bayer Ag	Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
US7019010B2 (en) *	2001-09-27	2006-03-28	Novertis Ag	Combinations
ATE431350T1 (de) *	2002-06-12	2009-05-15	Hoffmann La Roche	Amid substituierte xanthin derivate mit gluconeogenesis modulierender wirkung
KR101150449B1 (ko) *	2002-08-21	2012-06-01	베링거 잉겔하임 파르마 게엠베하 운트 코 카게	8-［3-아미노-피페리딘-1-일］-크산틴, 이의 제조방법 및 이를 포함하는 약제학적 조성물
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
ATE385234T1 (de) *	2003-02-19	2008-02-15	Hoffmann La Roche	Sulfonamidsubstituierte xanthinderivate zur verwendung als pepck-inhibitoren
US7148229B2 (en)	2003-02-19	2006-12-12	Hoffman-La Roche Inc.	Sulfonamide substituted xanthine derivatives
US7247639B2 (en) *	2003-06-06	2007-07-24	Endacea, Inc.	A1 adenosine receptor antagonists
KR100658080B1 (ko) *	2003-08-26	2006-12-15	비오이 하이디스 테크놀로지 주식회사	백라이트 조립용 지그
TW200605893A (en) *	2004-02-12	2006-02-16	Novartis Ag	Use of organic compounds
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US7915288B2 (en) *	2004-05-08	2011-03-29	Novartis International Pharmaceutical Ltd.	1-aryl-4-substituted isoquinolines
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005001989A1 (de) *	2005-01-15	2006-07-20	Bayer Healthcare Ag	Intravenöse Formulierungen von PDE-Inhibitoren
US7601723B2 (en) *	2005-02-25	2009-10-13	Pgx Health, Llc	Pyridyl substituted xanthines
US20070004745A1 (en) *	2005-03-25	2007-01-04	Schering-Plough Corporation	Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
KR20080065704A (ko)	2005-11-09	2008-07-14	콤비네이토릭스, 인코포레이티드	의학적 이상의 치료 방법들, 조성물들, 및 키트들
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
CA2810522A1 (en)	2006-05-04	2007-11-15	Boehringer Ingelheim International Gmbh	Polymorphs
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
EP2167057A1 (en) *	2007-06-13	2010-03-31	Bayer HealthCare AG	Pde inhibitors for the treatment of hearing impairment
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	Inibidor de dpp-4 e seu uso
CN102149407A (zh)	2008-09-10	2011-08-10	贝林格尔.英格海姆国际有限公司	治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CA2745037C (en)	2008-12-23	2020-06-23	Boehringer Ingelheim International Gmbh	Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8(3-(r)-amino-piperidin-1-yl)-xanthine
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
JP2012521411A (ja) *	2009-03-26	2012-09-13	マピファーマリミテッド	アログリプチンの調製プロセス
AU2010323068B2 (en)	2009-11-27	2015-09-03	Boehringer Ingelheim International Gmbh	Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
MX366325B (es)	2010-05-05	2019-07-05	Boehringer Ingelheim Int	Terapia de combinacion.
KR20230051307A (ko)	2010-06-24	2023-04-17	베링거 인겔하임 인터내셔날 게엠베하	당뇨병 요법
US9034883B2 (en)	2010-11-15	2015-05-19	Boehringer Ingelheim International Gmbh	Vasoprotective and cardioprotective antidiabetic therapy
EP2675791B1 (en) *	2011-02-18	2016-02-17	Allergan, Inc.	Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US8962636B2 (en)	2011-07-15	2015-02-24	Boehringer Ingelheim International Gmbh	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
EP3685839A1 (en)	2012-05-14	2020-07-29	Boehringer Ingelheim International GmbH	Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014071044A1 (en) *	2012-11-01	2014-05-08	Allergan, Inc.	Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
WO2015128453A1 (en)	2014-02-28	2015-09-03	Boehringer Ingelheim International Gmbh	Medical use of a dpp-4 inhibitor
WO2017211979A1 (en)	2016-06-10	2017-12-14	Boehringer Ingelheim International Gmbh	Combinations of linagliptin and metformin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2558162B1 (fr) *	1984-01-17	1986-04-25	Adir	Nouveaux derives de la xanthine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
GB9311920D0 (en) *	1993-06-09	1993-07-28	Pfizer Ltd	Therapeutic agents
AU4501199A (en) *	1998-06-03	1999-12-20	Almirall Prodesfarma S.A.	8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
GB9828340D0 (en) *	1998-12-22	1999-02-17	Novartis Ag	Organic compounds

2000
- 2000-04-07 GB GBGB0008694.2A patent/GB0008694D0/en not_active Ceased
2001
- 2001-04-05 CA CA002403514A patent/CA2403514C/en not_active Expired - Fee Related
- 2001-04-05 RU RU2002129557/04A patent/RU2269529C2/ru not_active IP Right Cessation
- 2001-04-05 AU AU7392101A patent/AU7392101A/xx active Pending
- 2001-04-05 CN CNB018074898A patent/CN1176922C/zh not_active Expired - Fee Related
- 2001-04-05 DK DK01940294T patent/DK1268480T3/da active
- 2001-04-05 AT AT01940294T patent/ATE253576T1/de active
- 2001-04-05 CZ CZ20023305A patent/CZ20023305A3/cs unknown
- 2001-04-05 PE PE2001000317A patent/PE20020228A1/es not_active Application Discontinuation
- 2001-04-05 WO PCT/EP2001/003909 patent/WO2001077110A1/en active IP Right Grant
- 2001-04-05 MY MYPI20011632A patent/MY119238A/en unknown
- 2001-04-05 EP EP01940294A patent/EP1268480B1/en not_active Expired - Lifetime
- 2001-04-05 AU AU2001273921A patent/AU2001273921B2/en not_active Ceased
- 2001-04-05 JP JP2001575583A patent/JP3869725B2/ja not_active Expired - Fee Related
- 2001-04-05 HU HU0300565A patent/HUP0300565A3/hu unknown
- 2001-04-05 PL PL358205A patent/PL212407B1/pl unknown
- 2001-04-05 DE DE60101158T patent/DE60101158T2/de not_active Expired - Lifetime
- 2001-04-05 IL IL15207801A patent/IL152078A0/xx unknown
- 2001-04-05 NZ NZ521361A patent/NZ521361A/en unknown
- 2001-04-05 MX MXPA02009903A patent/MXPA02009903A/es active IP Right Grant
- 2001-04-05 KR KR10-2002-7012627A patent/KR100526094B1/ko not_active IP Right Cessation
- 2001-04-05 PT PT01940294T patent/PT1268480E/pt unknown
- 2001-04-05 TR TR2004/00185T patent/TR200400185T4/xx unknown
- 2001-04-05 US US10/240,481 patent/US20030171384A1/en not_active Abandoned
- 2001-04-05 ES ES01940294T patent/ES2210169T3/es not_active Expired - Lifetime
- 2001-04-05 AR ARP010101623A patent/AR028531A1/es not_active Application Discontinuation
- 2001-04-05 SK SK1428-2002A patent/SK14282002A3/sk unknown
- 2001-04-05 BR BR0109855-1A patent/BR0109855A/pt not_active IP Right Cessation
2002
- 2002-10-02 NO NO20024741A patent/NO20024741L/no not_active Application Discontinuation
- 2002-10-03 ZA ZA200207956A patent/ZA200207956B/en unknown

Also Published As

Publication number	Publication date
HUP0300565A3 (en)	2004-10-28
CN1176922C (zh)	2004-11-24
AR028531A1 (es)	2003-05-14
TR200400185T4 (tr)	2004-03-22
AU7392101A (en)	2001-10-23
RU2002129557A (ru)	2004-03-27
AU2001273921B2 (en)	2005-05-05
CA2403514C (en)	2010-01-12
GB0008694D0 (en)	2000-05-31
WO2001077110A1 (en)	2001-10-18
EP1268480B1 (en)	2003-11-05
IL152078A0 (en)	2003-05-29
PL358205A1 (en)	2004-08-09
BR0109855A (pt)	2003-06-03
DE60101158D1 (en)	2003-12-11
US20030171384A1 (en)	2003-09-11
ZA200207956B (en)	2003-07-16
JP2003530398A (ja)	2003-10-14
DK1268480T3 (da)	2004-03-15
NO20024741D0 (no)	2002-10-02
SK14282002A3 (sk)	2003-04-01
EP1268480A1 (en)	2003-01-02
JP3869725B2 (ja)	2007-01-17
MXPA02009903A (es)	2003-03-27
NZ521361A (en)	2004-05-28
PL212407B1 (pl)	2012-09-28
CA2403514A1 (en)	2001-10-18
MY119238A (en)	2005-04-30
KR20020081590A (ko)	2002-10-28
CZ20023305A3 (cs)	2003-01-15
NO20024741L (no)	2002-10-02
ATE253576T1 (de)	2003-11-15
RU2269529C2 (ru)	2006-02-10
DE60101158T2 (de)	2004-08-26
ES2210169T3 (es)	2004-07-01
PE20020228A1 (es)	2002-03-28
KR100526094B1 (ko)	2005-11-08
CN1420887A (zh)	2003-05-28
HUP0300565A2 (hu)	2003-07-28

Publication	Publication Date	Title
PT1268480E (pt)	2004-03-31	Derivados de 8-quinolinil-xantina e 8-isoquinolinil-xantina como inibidores da pde 5
AR028576A1 (es)	2003-05-14	Derivados de b-carbolina utiles como inhibidores de fosfodiesterasa
AR028575A1 (es)	2003-05-14	Derivados de pirrolopiridinona utiles como inhibidores de fosfodiesterasa
ATE540013T1 (de)	2012-01-15	Naphthalinderivate
AR028567A1 (es)	2003-05-14	Nuevos derivados de fenil-propargileter
DK1292604T3 (da)	2009-06-15	2-Aminocarbonyl-9H-purinderivater
PT1287001E (pt)	2004-12-31	Derivados de tiofeno uteis como agentes anticancerigenos
AR028596A1 (es)	2003-05-14	Nuevos derivados de fenilglicina
PT1303521E (pt)	2005-05-31	Derivados de tetra-hidro-heterocicloazepinil-pirimidina
AR027967A1 (es)	2003-04-16	Derivados de esteres de pirazol como agentes antinflamatorios/analgesicos
PT1244641E (pt)	2005-08-31	Derivados da tiazolilamida
ATE298332T1 (de)	2005-07-15	Decahydro-isochinolinderivate
DK1280809T3 (da)	2005-11-07	Antitumorecteinascidinderivater
PT1187814E (pt)	2004-10-29	Derivados da 5-fenil-pirimidina
PT1178986E (pt)	2004-07-30	Derivados da furanona como inibidores da catepsina s
PT1189907E (pt)	2005-05-31	Tienopirimidinas como inibidores da fosfodiesterase
FR2810318B1 (fr)	2005-09-23	Derives de diamano-phenothiazine
DE50114491D1 (de)	2008-12-24	Substituierte C-Cyclohexylmethylamin-Derivative
AR028602A1 (es)	2003-05-14	Derivados de pirrol
AR028282A1 (es)	2003-04-30	Derivados de aminofenil pirimidona
PT1322592E (pt)	2004-12-31	Derivados substituidos de 1-aminobutan-3-ol
ATE282021T1 (de)	2004-11-15	Substituierte aminomethyl-phenyl- cyclohexanderivate
PT1339695E (pt)	2006-08-31	Inibidores da farnesiltransferase
PT1246791E (pt)	2005-03-31	Derivados de aminometilfenilciclo-hexanona
PT1330453E (pt)	2006-07-31	Derivados de indolilpiperidina como agentes anti-histaminicos e antialergicos